

# Encouraging Innovation

## for Rare Disease Patients




Only 5% of rare diseases have an FDA-approved treatment option, making additional innovation crucial.



Patients with rare diseases rely on policies that encourage research and development of treatment options.

Policymakers can encourage innovation through:



**Preservation of User Fee Acts** that expand the capacity of the FDA to approve drugs



**Support for policies** that limit unintended consequences of the Inflation Reduction Act



**Protection of the Accelerated Approval Pathway** which speeds up FDA review

The future of rare disease relies on patient-centered policies.

